Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ARVN Arvinas Holding Company LLC

Market Closed 04-04 16:00:00 EDT

6.56

-0.34

-4.93%

盘后6.57

+0.01+0.15%

19:53 EDT

High6.80	Low6.24	Vol3.09M
Open6.68	D1 Closing6.90	Amplitude8.12%
Mkt Cap451.14M	Tradable Cap352.17M	Total Shares68.77M
T/O20.09M	T/O Rate5.75%	Tradable Shares53.69M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ARVN","market":"US","secType":"STK","nameCN":"Arvinas Holding Company LLC","latestPrice":6.56,"timestamp":1743796800000,"preClose":6.9,"halted":0,"volume":3087845,"hourTrading":{"tag":"盘后","latestPrice":6.57,"preClose":6.56,"latestTime":"19:53 EDT","volume":26376,"amount":173059.44,"timestamp":1743810782970},"delay":0,"floatShares":53685100,"shares":68771867,"eps":-2.766342,"marketStatus":"Market Closed","change":-0.34,"latestTime":"04-04 16:00:00 EDT","open":6.68,"high":6.8,"low":6.24,"amount":20086929.7943985,"amplitude":0.081159,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.766342,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1744012800000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1538020800000,"exchange":"NASDAQ","adjPreClose":6.9,"preHourTrading":{"tag":"盘前","latestPrice":6.73,"preClose":6.9,"latestTime":"09:29 EDT","volume":1751,"amount":11751.3399164,"timestamp":1743773362530},"postHourTrading":{"tag":"盘后","latestPrice":6.57,"preClose":6.56,"latestTime":"19:53 EDT","volume":26376,"amount":173059.44,"timestamp":1743810782970},"volumeRatio":1.0567513545847345,"impliedVol":1.1985,"impliedVolPercentile":0.8446},"requestUrl":"/m/hq/s/ARVN","defaultTab":"news","newsList":[{"id":"2525329377","title":"Arvinas Potential Parkinson's Treatment Shows Positive Data In Human Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2525329377","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525329377?lang=en_us&edition=full_marsco","pubTime":"2025-04-05 03:38","pubTimestamp":1743795511,"startTime":"0","endTime":"0","summary":"Arvinas, Inc. unveiled first-in-human data on Friday for its experimental Parkinson’s disease treatment, ARV-102.Results from the randomized, double-blind, placebo-controlled single ascending dose  cohort of the Phase 1 healthy volunteer trial and initial results from the multiple ascending dose  cohort were shared in a presentation at the 2025 International Conference on Alzheimer’s and Parkinson’s Diseases.The Phase 1 trial included SAD cohorts from 10 mg to 200 mg and MAD cohorts of 10 mg to 80 mg in healthy volunteers.In the trial ARV-102, the company’s investigational PROteolysis TArgeting Chimera  leucine-rich repeat kinase 2  degrader, demonstrated substantial reduction of LRRK2, a multifunctional protein that has been implicated in Parkinson’s disease and progressive supranuclear palsy , in cerebral spinal fluid .Also Read: Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial. While LRRK2 is primarily known for its role in Parkinson’s, Arv","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arvinas-potential-parkinsons-treatment-shows-193831011.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ARVN","PSP","CSF"],"gpt_icon":0},{"id":"2524205150","title":"Arvinas Says First-in-Human Data for ARV-102 Shows Substantial Reduction of LRRK2","url":"https://stock-news.laohu8.com/highlight/detail?id=2524205150","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524205150?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:56","pubTimestamp":1743767815,"startTime":"0","endTime":"0","summary":"Arvinas  said Friday that data from the first-in-human clinical trial of ARV-102 demonstrated substantial reduction of leucine-rich repeat kinase 2, or LRRK2, a multifunctional protein that has been primarily implicated in Parkinson's disease.ARV-102 was generally safe and well tolerated with no serious adverse events reported after single or multiple doses, the company said.At a single oral dose of at least 60 mg, and once daily repeated oral doses of at least 20 mg, ARV-102 achieved greater than 50% LRRK2 reduction in the cerebral spinal fluid and greater than 90% LRRK2 reduction in the peripheral blood mononuclear cells.The company said its findings support continued evaluation of ARV-102 in neurodegenerative diseases associated with LRRK2 dysfunction and a phase 1 trial in patients with Parkinson's disease has been initiated and is currently enrolling.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2524208018","title":"Arvinas presents first-in-human data from ARV-102 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2524208018","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524208018?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:10","pubTimestamp":1743765045,"startTime":"0","endTime":"0","summary":"Arvinas (ARVN) presented data from the first-in-human clinical trial of ARV-102, the Company’s investigational PROteolysis TArgeting Chimera leucin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/arvinas-presents-first-in-human-data-from-arv-102-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/arvinas-presents-first-in-human-data-from-arv-102-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2524332208","title":"Arvinas Inc -Data Demonstrate That Arv-102 Was Well Tolerated","url":"https://stock-news.laohu8.com/highlight/detail?id=2524332208","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524332208?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:00","pubTimestamp":1743764430,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI01O:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2524208336","title":"Arvinas Inc -Arv-102 Achieved Central and Peripheral Lrrk2 Reduction Indicating Substantial Lrrk2 Protein Degradation in Healthy Volunteers","url":"https://stock-news.laohu8.com/highlight/detail?id=2524208336","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524208336?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:00","pubTimestamp":1743764430,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI01O:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2524208330","title":"Arvinas Presents First-in-Human Data for Investigational Oral Protac Arv-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral Lrrk2 Degradation","url":"https://stock-news.laohu8.com/highlight/detail?id=2524208330","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524208330?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:00","pubTimestamp":1743764430,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI01O:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ARVN","BK4007"],"gpt_icon":0},{"id":"2524083482","title":"Arvinas-Expects to Complete Enrollment and Present Initial Data From Ongoing Sad Cohort of Phase 1 Clinical Trial in Patients With Pd in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2524083482","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524083482?lang=en_us&edition=full_marsco","pubTime":"2025-04-04 19:00","pubTimestamp":1743764430,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250404:nFWN3QI01O:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2524598262","title":"We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2524598262","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524598262?lang=en_us&edition=full_marsco","pubTime":"2025-04-03 19:52","pubTimestamp":1743681168,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while the successes are well known, investors should not ignore the very many unprofitable companies that simply burn through all their cash and collapse.So should Arvinas  shareholders be worried about its cash burn?In this article, we define cash burn as its annual  free cash flow, which is the amount of money a company spends each year to fund its growth. Let's start with an examination of the business' cash, relative to its cash burn.This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.Since it has a market capitalisation of US$483m, Arvinas' US$261m in cash burn equates to about 54% of its market value. That's high expenditure relative t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/think-arvinas-nasdaq-arvn-afford-115248827.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4112","BK4007","LU2095319765.USD","IE00B3QW5Z07.USD","NDAQ","MNQmain","LU2210149790.SGD","QID","IE00B64PRP62.GBP",".IXIC","ARVN","LU2210150020.SGD","IE00BKPKM429.USD","BK4585","TSYW.SI","USJW.SI","TQQQ","USAW.SI","NVIW.SI","QQQ","QLD","SQQQ","NQmain","BK4588","PSQ","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2522375533","title":"Arvinas Announces Oral Presentation at 2025 International Conference on  Alzheimer’s & Parkinson’s Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2522375533","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522375533?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073224,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nTUAGWDT6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2522759013","title":"Arvinas Announces Oral Presentation at 2025 International Conference on  Alzheimer’s & Parkinson’s Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2522759013","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522759013?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:00","pubTimestamp":1743073200,"startTime":"0","endTime":"0","summary":"– Company to highlight first-in-human data from healthy volunteers in both the single-ascending and multiple-ascending dose portions of a Phase 1 study of ARV-102, an investigational PROTAC LRRK2 degrader –。NEW HAVEN, Conn., March 27, 2025  -- Arvinas, Inc. , a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that data from the first-in-human study evaluating single-ascending and multiple-ascending doses in healthy volunteers of ARV-102 will be presented at the International Conference on Alzheimer’s and Parkinson’s Diseases , April 1-5, 2025 in Vienna, Austria.ARV-102 is Arvinas’ investigational PROteolysis TArgeting Chimera  degrader targeting leucine-rich repeat kinase 2 , a multifunctional protein that has been implicated in Parkinson’s disease and progressive supranuclear palsy.Session Title: First-In-Human Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of ARV-102, a PROTAC LRRK2","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arvinas-announces-oral-presentation-2025-110000880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","ARVN"],"gpt_icon":0},{"id":"2522303387","title":"Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), Eledon Pharmaceuticals (ELDN) and Arcutis Biotherapeutics (ARQT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522303387","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522303387?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 08:30","pubTimestamp":1742862623,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Arvinas Holding Company (ARVN – Research Report), El...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arvinas-holding-company-arvn-eledon-pharmaceuticals-eldn-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-arvinas-holding-company-arvn-eledon-pharmaceuticals-eldn-and-arcutis-biotherapeutics-arqt?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","ARVN","ARQT","ELDN","HCSG","BK4007","BK4139"],"gpt_icon":0},{"id":"2521237298","title":"BUZZ-Arvinas falls after Leerink's price target cut","url":"https://stock-news.laohu8.com/highlight/detail?id=2521237298","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521237298?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 01:15","pubTimestamp":1742577356,"startTime":"0","endTime":"0","summary":"BUZZ-Arvinas falls after Leerink's price target cut** Shares of drug developer Arvinas ARVN.O fall 3.4% to $8.70** Brokerage Leerink lowers PT to $12 from $49, maintains \"outperform\" rating** Despite disappointing topline results for vepdegestrant, staying the course and remaining outperform pending detailed data release and visibility on a number of key value levers - Leerink** Vepdegestrant, ARVN and Pfizer's PFE.N oral drug,  failed to delay progression of breast cancer in patients with most common type of the disease in a late-stage trial last week** It is too early to assume that vepdeg is inferior to elacestrant, as the failure in the intention-to-treat population could have been driven by a number of factors - brokerage** Elacestrant is used to treat certain types of hormone receptor-positive breast cancer** As of last close, ARVN down 53% YTD  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250321:nL4N3Q41BU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN"],"gpt_icon":1},{"id":"2521462258","title":"OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek","url":"https://stock-news.laohu8.com/highlight/detail?id=2521462258","media":"Zacks","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521462258?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 00:44","pubTimestamp":1742575440,"startTime":"0","endTime":"0","summary":"Shares of OptiNose OPTN soared 52.5% on Thursday after the company announced that it is set to be acquired by Paratek Pharmaceuticals, a private biotech. This deal will add OPTN’s approved product, Xhance , to the latter’s commercial portfolio.Xhance is an innovative drug-device therapy for chronic rhinosinusitis , with or without nasal polyps. Utilizing its proprietary Exhalation Delivery System, it delivers a corticosteroid directly to the site of inflammation, improving patient outcomes while potentially reducing the need for invasive or costly treatments.The acquisition enables OptiNose to expand Xhance’s market reach, addressing long-standing challenges in adoption. Paratek’s strong commercial infrastructure will help drive awareness, particularly among primary care providers who treat most CRS patients.Paratek’s recently expanded primary care field force, combined with OptiNose’s specialist sales expertise, positions the company to accelerate Xhance’s adoption across both ear, no","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/optn-stock-soars-53-inking-164400660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1585245621.USD","LU1839511570.USD","LU0320765992.SGD","IE00B7SZL793.SGD","ARVN","IE00B3T34201.USD","IE0031619046.USD","BK4588","LU0889565916.HKD","LU2087621335.USD","BK4566","BK4585","BK4550","IE00BKVL7J92.USD","LU1571399168.USD","LU1066051498.USD","IE00B66KJ199.SGD","LU2089984988.USD","GILD","BK4578","CRS","LU2468319806.SGD","LU1430594728.SGD","BK4583","BK4007","BK4532","IE00B19Z4B17.USD","OPTN","LU0058720904.USD","BK4568","IE00BZ1G4Q59.USD","LU0109394709.USD","LU0234570918.USD","LU1066053197.SGD","IE00B19Z3B42.SGD","DVAX","BK4006","IE0002270589.USD","IE00B19Z3581.USD","LU2065731478.USD","LU0289739699.SGD","IE00B7SZLL34.SGD","IE00BSNM7G36.USD","BK4139"],"gpt_icon":0},{"id":"2521461815","title":"IMVT Unlikely to Pursue Batoclimab for MG & CIDP Despite Success","url":"https://stock-news.laohu8.com/highlight/detail?id=2521461815","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521461815?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 22:19","pubTimestamp":1742480340,"startTime":"0","endTime":"0","summary":"Immunovant IMVT announced top-line data from a late-stage study of its investigational candidate, batoclimab, for myasthenia gravis  and initial results from Period 1 of a mid-stage study of the same candidate for chronic inflammatory demyelinating polyneuropathy .IMVT’s Batoclimab Shows Superior Efficacy in MG Patients. The phase III study is evaluating the efficacy and safety of batoclimab in adult patients with moderate to severe MG. Per the data readout, the study met its primary endpoint of mean change from baseline in the MG Activities of Daily Living  score, used to determine the impact of weekly or bi-monthly doses of batoclimab, in acetylcholine receptor antibody positive  patients after 12 weeks.Immunovant reported that MG patients who received the weekly680mg subcutaneous dose of batoclimab achieved a 5.6-point improvement in MG-ADL and a 4.7-point improvement was observed in patients receiving the 340mg dose compared to a 3.6-point improvement in the placebo group at week 1","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/imvt-unlikely-pursue-batoclimab-mg-141900033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2087621335.USD","LU0109394709.USD","LU1585245621.USD","LU1571399168.USD","DVAX","IE0002270589.USD","IMVT","IE00B19Z3B42.SGD","LU0234570918.USD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4123","IE00BKVL7J92.USD","IE00BZ1G4Q59.USD","LU0289739699.SGD","LU0889565916.HKD","LU2468319806.SGD","IE00B66KJ199.SGD","BK4007","BK4585","BK4532","BK4139","IE00B3T34201.USD","LU1430594728.SGD","IE0031619046.USD","GILD","BK4578","LU0058720904.USD","ARVN","BK4583","BK4588","IE00B7SZL793.SGD","LU0320765992.SGD","LU1839511570.USD","IE00BSNM7G36.USD","BK4568","LU1066053197.SGD","MG","BK4566","IE00B19Z4B17.USD","LU2089984988.USD","LU1066051498.USD","BK4550"],"gpt_icon":0},{"id":"2520855157","title":"JNJ's Nipocalimab Gets FDA's Fast Track Tag for Sjogren's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2520855157","media":"Zacks","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520855157?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 22:59","pubTimestamp":1742396340,"startTime":"0","endTime":"0","summary":"Johnson & Johnson JNJ announced that the FDA has granted a Fast Track designation  to its investigational drug, nipocalimab, for treating adult patients with moderate-to-severe Sjgren’s disease , a chronic autoimmune disease.Currently, there are no advanced therapies approved by the FDA for the given indication.The Fast Track designation from the FDA facilitates rapid development and expedites the review of drug candidates that are being developed to treat serious conditions and for which clinical data demonstrate the potential to address unmet medical needs. The goal is to make these treatments rapidly available to patients in need.Besides SjD, the FDA has granted FTD to nipocalimab in three other indications, hemolytic disease of the fetus and newborn  and warm autoimmune hemolytic anemia , generalized myasthenia gravis  and fetal neonatal alloimmune thrombocytopenia.The FDA granted Breakthrough Therapy designation to nipocalimab for SjD in November 2024. In February this year, J&J a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jnjs-nipocalimab-gets-fdas-fast-145900660.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1929549753.HKD","LU1430594728.SGD","SG9999001440.SGD","IE00BZ1G4Q59.USD","LU1066053197.SGD","LU0345770993.USD","LU1894683264.USD","LU1674673428.USD","LU2430703095.HKD","LU0234572021.USD","BK4007","LU1894683348.USD","DVAX","SG9999002224.SGD","BK4567","LU1732800096.USD","IE00B2B36J28.USD","LU1244550221.USD","LU0889565916.HKD","LU1839511570.USD","LU0109394709.USD","IE00BGHQF631.EUR","LU0122379950.USD","LU2112291526.USD","FAST","LU0912757837.SGD","IE000M9KFDE8.USD","LU1023059063.AUD","ARVN","LU0320765646.SGD","IE00B3T34201.USD","BK4588","LU2133065610.SGD","IE00BJJMRZ35.SGD","LU2347655156.SGD","LU0792757196.USD","LU1571399168.USD","JNJ","LU0289739699.SGD","BK4533","GILD","IE00B1BXHZ80.USD","IE00BKVL7J92.USD","LU1032955483.USD","LU0320765992.SGD","LU1914381329.SGD","LU0889566641.SGD","LU0640476718.USD","LU2430703251.USD","IE00BVYPNW00.USD"],"gpt_icon":0},{"id":"2520570285","title":"AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2520570285","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520570285?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 23:10","pubTimestamp":1742224200,"startTime":"0","endTime":"0","summary":"AstraZeneca AZN recently announced that the European Commission has approved its blockbuster cancer drug Imfinzi  as monotherapy for treating limited-stage small cell lung cancer  in adult patients whose disease has not progressed following platinum-based chemoradiation therapy .The latest approval for Imfinzi in the European Union  was based on data from the phase III ADRIATIC study.Data from the phase III ADRIATIC study showed that treatment with Imfinzi reduced the risk of death by 27% as compared to placebo. Additionally, treatment with Imfinzi reduced the risk of disease progression or death by 24% versus placebo.The approval in the EU was expected as the Committee for Medicinal Products for Human Use recommended approval of Imfinzi as monotherapy for treating LS-SCLC in adult patients whose disease has not progressed following platinum-based CRT in February 2025.The FDA approved Imfinzi for a similar indication in December 2024.Hypoparathyroidism patients suffer from a deficiency","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/azns-imfinzi-gets-eu-nod-151000804.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BMRN","CRT","BK4568","BK4585","BK4007","LU2417539215.USD","LU2462157665.USD","DVAX","IE00B19Z3B42.SGD","BK4566","LU0889565916.HKD","BK4213","LU0109394709.USD","BK4139","IE00B19Z3581.USD","AZN","BK4156","ARVN","IE0002270589.USD","IE00B7SZLL34.SGD","BK4588","LU2456880835.USD","SSI","LU1829250122.USD","LU2236285917.USD","LU0320765992.SGD"],"gpt_icon":0},{"id":"2520574575","title":"Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?","url":"https://stock-news.laohu8.com/highlight/detail?id=2520574575","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520574575?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 21:51","pubTimestamp":1742219460,"startTime":"0","endTime":"0","summary":"BioHarvest Sciences Inc.  shares ended the last trading session 12.7% higher at $5.85. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 7.3% loss over the past four weeks.Earlier this month, the company announced data from an in vitro test on its proprietary new Olive Cell compound, which demonstrated reduced fat accumulation in human liver cells. Fat accumulation in the liver is a leading cause of non-alcohol fatty liver disease, which affects around 30-40% of adults in the United States. This might have driven the recent share price rally.BioHarvest Sciences Inc. is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, Arvinas, Inc. , finished the last trading session 1.4% lower at $8.43. ARVN has returned -51.6% over the past month.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strength-seen-bioharvest-sciences-inc-135100013.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4183","ARVN","BHST","BK4007"],"gpt_icon":0},{"id":"2520575703","title":"Down -53.96% in 4 Weeks, Here's Why Arvinas (ARVN) Looks Ripe for a Turnaround","url":"https://stock-news.laohu8.com/highlight/detail?id=2520575703","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520575703?lang=en_us&edition=full_marsco","pubTime":"2025-03-17 21:35","pubTimestamp":1742218505,"startTime":"0","endTime":"0","summary":"Arvinas, Inc.  has been beaten down lately with too much selling pressure. While the stock has lost 54% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.We use Relative Strength Index , one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.The heavy selling of ARVN shares appears to be in the process of exhausting itself, as indicated by its RSI reading of 24.51. So,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/down-53-96-4-weeks-133505474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ARVN","BK4007","RSI","BK4150"],"gpt_icon":0},{"id":"2519863822","title":"Pharma Stock Roundup: RHHBY Obesity Drug Rights Buyout, NVO Pipeline Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2519863822","media":"Zacks","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519863822?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 01:05","pubTimestamp":1741885500,"startTime":"0","endTime":"0","summary":"This week, Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche RHHBY announced a license and collaboration deal with Denmark’s Zealand Pharma to co-develop its lead obesity candidate petrelintide. Pfizer PFE and partner Arvinas ARVN announced mixed phase III data for breast cancer therapy, vepdegestrant. J&J JNJ and partner Protagonist Therapeutics’ investigational targeted oral peptide, icotrokinra met the primary endpoint of clinical response in ulcerative colitis study.Here's a recap of the week’s most important stories.NVO's Novel Obesity Treatment Disappoints in Phase III Study. Novo Nordisk’sphase III REDEFINE 2 study evaluating its next-gen subcutaneous obesity candidate, CagriSema, met its primary endpoint. CagriSema is a fixed-dose combination of a long-acting amylin analog, cagrilintide  and semaglutide .In the study, 61.9% of patients were given the highest dose of the drug.For the deal, Roche will make an upfro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/pharma-stock-roundup-rhhby-obesity-170500925.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999003800.SGD","ZLDPF","SG9999011175.SGD","LU1430594728.SGD","LU2505996509.AUD","LU0058720904.USD","MBC","LU0345770993.USD","LU1894683264.USD","LU2089984988.USD","LU1066051811.HKD","IE00B42XCP33.USD","LU2430703095.HKD","LU0345769631.USD","BK4007","BK4559","LU0054578231.USD","LU1732799900.SGD","LU0345769128.USD","RHHBY","LU0053671581.USD","ITT","LU0795875086.SGD","LU2602419157.SGD","LU1261432733.SGD","IE00BGHQF631.EUR","IE00B4R5TH58.HKD","LU2112291526.USD","LU0912757837.SGD","IE00B19Z3581.USD","IE00BLSP4239.USD","SG9999002232.USD","ARVN","PFE","SG9999001176.USD","LU1093756168.USD","BK4599","LU0234570918.USD","JNJ","LU0225284248.USD","LU1032466523.USD","BK4581","03165","LU1032955483.USD","LU1718418525.SGD","LU2129689605.HKD","NVO","LU0466842654.USD","LU1244550221.USD","IE00BDGV0183.EUR"],"gpt_icon":1},{"id":"2519859522","title":"Arvinas Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2519859522","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519859522?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:51","pubTimestamp":1741881060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ARVN/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 13, 2025 11:51 ET (15:51 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARVN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arvinas.com","stockEarnings":[{"period":"1week","weight":-0.1357},{"period":"1month","weight":-0.625},{"period":"3month","weight":-0.68},{"period":"6month","weight":-0.7372},{"period":"1year","weight":-0.8269},{"period":"ytd","weight":-0.6578}],"compareEarnings":[{"period":"1week","weight":-0.0907},{"period":"1month","weight":-0.1334},{"period":"3month","weight":-0.1464},{"period":"6month","weight":-0.1182},{"period":"1year","weight":-0.0152},{"period":"ytd","weight":-0.1379}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.025374},{"month":2,"riseRate":0.571429,"avgChangeRate":0.011057},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.187738},{"month":4,"riseRate":0.428571,"avgChangeRate":0.034272},{"month":5,"riseRate":0.5,"avgChangeRate":-0.112391},{"month":6,"riseRate":0.833333,"avgChangeRate":0.011275},{"month":7,"riseRate":0.666667,"avgChangeRate":0.126111},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.076544},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.103315},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.018156},{"month":11,"riseRate":0.714286,"avgChangeRate":0.161248},{"month":12,"riseRate":0.571429,"avgChangeRate":0.407187}],"exchange":"NASDAQ","name":"Arvinas Holding Company LLC","nameEN":"Arvinas Holding Company LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Arvinas Holding Company LLC(ARVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Arvinas Holding Company LLC,ARVN,Arvinas Holding Company LLC股票,Arvinas Holding Company LLC股票老虎,Arvinas Holding Company LLC股票老虎国际,Arvinas Holding Company LLC行情,Arvinas Holding Company LLC股票行情,Arvinas Holding Company LLC股价,Arvinas Holding Company LLC股市,Arvinas Holding Company LLC股票价格,Arvinas Holding Company LLC股票交易,Arvinas Holding Company LLC股票购买,Arvinas Holding Company LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arvinas Holding Company LLC(ARVN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Arvinas Holding Company LLC(ARVN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction